Participant List

**Paul Ambrose**  
President, Institute for Clinical Pharmacodynamics and Honorary Research Professor, University of Oxford College of Medicine

**Danny Benjamin**  
Professor of Pediatrics and Faculty Associate Director, Duke Clinical Research Institute, Duke University School of Medicine

**John Bradley**  
Professor and Chief, Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego, School of Medicine and Director, Division of Infectious Diseases, Rady Children's Hospital San Diego

**Robert Califf**  
Vice Chancellor for Clinical and Translational Research, Director of the Duke Translational Medicine Institute, Duke University Medical Center

**Deborah Collyar**  
President, Patient Advocates In Research

**Heather Colvin**  
Senior Research Associate, Engelberg Center for Health Care Reform, The Brookings Institution

**Allan Coukell**  
Director, Medical Programs, Pew Health Group, The Pew Charitable Trusts

**Edward Cox**  
Director, Office of Antimicrobial Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Ralph D’Agostino**  
Chairman, Mathematics and Statistics Department, and Professor of Mathematics/Statistics, Biostatistics, and Epidemiology, Boston University

**Gregory Daniel**  
Managing Director and Fellow, Engelberg Center for Health Care Reform, The Brookings Institution

**Robert Danner**  
Senior Investigator and Head, Infectious Diseases Section, Critical Care Medicine Department, National Institutes of Health Clinical Center

**Dennis M. Dixon**  
Chief, Bacteriology and Mycology Branch, National Institute of Allergy and Infectious Disease, National Institutes of Health

**Mike Dudley**  
Senior Vice President, Research & Development and Chief Scientific Officer, Rempex Pharmaceuticals, Inc.

**Michael Dunne**  
Chief Medical Officer, Durata Therapeutics

**Barry Eisenstein**  
Senior Vice President of Scientific Affairs, Cubist Pharmaceuticals and Clinical Professor of Medicine, Harvard Medical School

**John Farley**  
Deputy Director, Office of Antimicrobial Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Thomas Fleming**  
Professor, Department of Biostatistics, University of Washington School of Public Health

**Vance Fowler Jr.**  
Professor, Department of Medicine – Infectious Diseases, Duke University

**David Friedland**  
Vice President, Clinical Sciences, Cerexa, Inc.
David N. Gilbert  
Chief of Infectious Diseases and Director, Earle A. Chiles Research Institute, Providence Portland Medical Center and Professor of Medicine, Oregon Health and Sciences University

Mark Goldberger  
Divisional Vice President, Regulatory Policy and Intelligence, Abbott Pharmaceuticals

Mohammad Huque  
Director, Division of Biometrics IV, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Dmitri Iarikov  
Medical Officer, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Audrey Jackson  
Senior Program Officer, Science and Research, Infectious Diseases Society of America

John Jenkins  
Director, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Larry Kocot  
Deputy Director, Engelberg Center for Health Care Reform, Visiting Fellow, Economic Studies, The Brookings Institution

Katie Laessig  
Deputy Director for Safety, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Joe Larsen  
Chief, Broad Spectrum Antimicrobials (BSA) Program, Division of CBRN Medical Countermeasures, Biomedical Advanced Research and Development Authority

Lisa LaVange  
Director, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Dara Lieberman  
Senior Government Relations Manager, Trust for America’s Health

Ben Lorenz  
Medical Officer, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Mark McClellan  
Director, Engelberg Center for Health Care Reform, Senior Fellow, Economic Studies, and Leonard D. Schaeffer Chair in Health Policy Studies, The Brookings Institution

Kunal Merchant  
Senior Clinical Project Manager, Clinical Trials Transformation Initiative

Bob Meyer  
Vice President, Global Regulatory Strategy, Policy and Safety, Merck

Theresa Mullin  
Director, Office of Planning and Informatics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Sumati Nambiar  
Deputy Director for Safety, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Kevin Outterson  
Associate Professor of Health Law, Bioethics and Human Rights, Boston University School of Law

John Powers  
Senior Medical Scientist, Science Applications International Corporation in support of the National Institute of Allergy and Infectious Diseases, National Institutes of Health and Associate Clinical Professor of Medicine, George Washington University School of Medicine

Charlene Reed  
Founder and Chief Executive Officer, Foundation to Combat Antimicrobial Resistance

John Rex  
Infection Clinical Vice President, AstraZeneca Pharmaceuticals and Adjunct Professor of Medicine, University of Texas Medical School at Houston

Kellie Schoolar Reynolds  
Deputy Division Director, Division of Clinical Pharmacology IV, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Louis Rice
Chair, Department of Medicine, Warren Alpert Medical School of Brown University and Physician-in-Chief, Rhode Island Hospital and The Miriam Hospital

Melissa Robb
Associate Director for Regulatory Affairs, Office of Medical Policy Initiatives, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Leonard Sacks
Associate Director for Clinical Methodology, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Jonas Santiago
Analyst, Division of Medical Policy Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Rachel Sherman
Director, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

David Shlaes
Sole Proprietor and President, Anti-Infectives Consulting

Tom Smith
Lead Medical Officer, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Brad Spellberg
Associate Professor of Medicine, Division of General Internal Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

George Talbot
Principal, Talbot Advisors LLC

Bob Temple
Deputy Center Director for Clinical Science and Acting Deputy Director of the Office of Drug Evaluation I (ODE-I), Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Pamela Tenaerts
Executive Director, Clinical Trials Transformation Initiative

Jeanine Thomas
President and Founder, MRSA Survivors Network

Joe Toerner
Associate Director for Medical Affairs, Office of Antimicrobial Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

John Tomayko
Senior Medical Director, GlaxoSmithKline

Janet Woodcock
Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration